{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2018-11-15&_metadata=all&version=1&hansardHeading=Nusinersen", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "items" : [{"_about" : "http://data.parliament.uk/resources/1142736", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142736/answer", "answerText" : {"_value" : "<p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-09-09T17:25:25.583Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the appropriateness of the NICE criteria for assessing a patient's access to Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4609", "label" : {"_value" : "Biography information for Eleanor Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Wolverhampton South West"}
      , "tablingMemberPrinted" : [{"_value" : "Eleanor Smith"}
      ], "uin" : "284289"}
    , {"_about" : "http://data.parliament.uk/resources/1127499", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127499/answer", "answerText" : {"_value" : "<p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p><p> <\/p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE\u2019s Appraisal Committee\u2019s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-29", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "256255"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-29T10:38:01.16Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-05-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "256254"}
    , {"_about" : "http://data.parliament.uk/resources/1124901", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1124901/answer", "answerText" : {"_value" : "<p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-05-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL15577"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-17T11:07:46.62Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-05-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3785", "label" : {"_value" : "Biography information for Baroness Thomas of Winchester"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Thomas of Winchester"}
      ], "uin" : "HL15576"}
    , {"_about" : "http://data.parliament.uk/resources/1077279", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1077279/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is an independent body and develops its technology appraisal recommendations in accordance with its published methods and processes, including consultation with stakeholders. The Department is a stakeholder in all NICE technology appraisals and has the opportunity to provide input at set points in the process, in common with other stakeholders.<\/p><p>NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost-effective use of National Health Service resources. Biogen has now submitted a revised submission and a meeting of NICE\u2019s independent appraisal committee has been arranged for 6 March 2019 to consider the recommendations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-03-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-05T17:13:30.803Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has held with NICE on the cost-flexibility effectiveness calculations for the treatment Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "225455"}
    , {"_about" : "http://data.parliament.uk/resources/1077280", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1077280/answer", "answerText" : {"_value" : "<p>The Government wants National Health Service patients to be able to benefit from effective new medicines in a way that represents value for money to the taxpayer. The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Spinraza for the treatment of spinal muscular atrophy.<\/p><p>Discussions have been taking place between the manufacturer of Spinraza, Biogen, and NHS England to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost-effective use of NHS resources. Biogen has now submitted a revised submission for NICE\u2019s independent Appraisal and a meeting has been arranged for 6 March to consider the recommendations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-03-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-05T17:14:34.19Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the cost of spinal muscular atrophy treatment Spinraza is not a barrier in the appraisal process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "225456"}
    , {"_about" : "http://data.parliament.uk/resources/1064472", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1064472/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.<\/p><p> <\/p><p>NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE\u2019s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "224025"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-28T11:56:53.813Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the planned timescale is for patients to access Spinraza treatment for muscular atrophy types 2 and 3.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/320", "label" : {"_value" : "Biography information for Mr Adrian Bailey"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Bromwich West"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Adrian Bailey"}
      ], "uin" : "224024"}
    , {"_about" : "http://data.parliament.uk/resources/1064473", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1064473/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy, including types 2 and 3.<\/p><p> <\/p><p>NHS England and NICE have been in discussions with the manufacturer of Spinraza, Biogen, to explore whether there are commercial flexibilities that might enable NICE to recommend the drug as a clinically and cost effective use of NHS resources. Biogen has now submitted a revised submission for NICE\u2019s independent Appraisal Committee to consider and a meeting has been arranged for 6 March 2019 to consider the recommendations. In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-02-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "224024"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-02-28T11:56:53.86Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-02-20", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress has been made on concluding a managed access treatment agreement for the use of Spinraza for patients with spinal muscular atrophy types 2 and 3.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/320", "label" : {"_value" : "Biography information for Mr Adrian Bailey"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Bromwich West"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Adrian Bailey"}
      ], "uin" : "224025"}
    , {"_about" : "http://data.parliament.uk/resources/1027584", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1027584/answer", "answerText" : {"_value" : "<p>Departmental Ministers and officials have spoken to colleagues at the National Institute for Health and Care Excellence (NICE) on a number of occasions to enquire about the progress of the technology appraisal of nusinersen for the treatment of spinal muscular atrophy.<\/p><p> <\/p><p>On 12 November, following NICE\u2019s second appraisal committee meeting for nusinersen on Tuesday 23 October, NICE informed registered stakeholders that it and the manufacturer Biogen were continuing to progress discussions and as a result NICE was not in a position to provide the outcome of the committee\u2019s deliberations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-12-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-21T14:17:39.09Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-12-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions he has had with NICE on the (a) timeframe for the publication of decision of the NICE evaluation committee meeting held on 23 October 2018 in relation to Spinraza and (b) potential availability of Spinraza on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4516", "label" : {"_value" : "Biography information for Heidi Allen"}
      }
      , "tablingMemberConstituency" : {"_value" : "South Cambridgeshire"}
      , "tablingMemberPrinted" : [{"_value" : "Heidi Allen"}
      ], "uin" : "203346"}
    , {"_about" : "http://data.parliament.uk/resources/1015562", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1015562/answer", "answerText" : {"_value" : "<p>Departmental officials have had a number of discussions with colleagues in the National Institute for Health and Care Excellence (NICE) to enquire about progress of the ongoing appraisal of nusinersen (Spinraza) for the treatment of spinal muscular atrophy. Discussions between NHS England, NICE and Biogen (the company that manufactures nusinersen) are ongoing to seek to agree a commercial agreement that would enable NICE to recommend use of nusinersen as a clinically and cost effective use of National Health Service resources.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-12-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-05T16:27:43.843Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on its appraised criteria to facilitate progress towards a Managed Access Arrangement for Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4679", "label" : {"_value" : "Biography information for Neil O'Brien"}
      }
      , "tablingMemberConstituency" : {"_value" : "Harborough"}
      , "tablingMemberPrinted" : [{"_value" : "Neil O'Brien"}
      ], "uin" : "196306"}
    , {"_about" : "http://data.parliament.uk/resources/1007767", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007767/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).<\/p><p> <\/p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.<\/p><p> <\/p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE\u2019s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:13:09.58Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Nusinersen"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4249", "label" : {"_value" : "Biography information for Anne Marie Morris"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newton Abbot"}
      , "tablingMemberPrinted" : [{"_value" : "Anne Marie Morris"}
      ], "uin" : "191928"}
    ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-date=2018-11-15&version=1&hansardHeading=Nusinersen", "page" : 0, "startIndex" : 1, "totalResults" : 10, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}